TKIs may be option for Ph-like ALL.
A recently identified subtype of acute lymphoblastic leukemia called Ph-like ALL is driven by an assortment of genetic changes that activate kinase signaling--alterations that may be vulnerable to FDA-approved tyrosine kinase inhibitors.